AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY
Grant number: 628903 | Funding period: 2010 - 2015
Related publications (15)
Prognostic gene expression signature for high-grade serous ovarian cancer
J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, MP Intermaggio, HS Leong, S Chen, W Elatre, B Gilks, T Nazeran, M Volchek, RC Bentley, C Wang, DS Chiu, S Kommoss, SCY Leung, J Senz, A Lum, V Chow
BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies ..
Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-kappa B Pathway Activity: A Novel Approach to a Long-Standing Enigma
Laura van Lieshout, Anja van de Stolpe, Phyllis van der Ploeg, David Bowtell, Joanne de Hullu, Jurgen Piek
We investigated signal transduction pathway (STP) activity in high-grade serous ovarian carcinoma (HGSC) in relation to progressio..
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer
Moonsun Jung, Jixuan Gao, Leanna Cheung, Angelika Bongers, Klaartje Somers, Molly Clifton, Emma E Ramsay, Amanda J Russell, Emanuele Valli, Andrew J Gifford, Joshy George, Catherine J Kennedy, Matthew J Wakefield, Monique Topp, Gwo-Yaw Ho, Clare L Scott, David D Bowtell, Anna deFazio, Murray D Norris, Michelle Haber
Epithelial ovarian cancer (EOC) is a complex disease comprising discrete histological and molecular subtypes, for which survival r..
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Nicola S Meagher, Linyuan Wang, Peter F Rambau, Maria P Intermaggio, David G Huntsman, Lynne R Wilkens, Mona A El-Bahrawy, Roberta B Ness, Kunle Odunsi, Helen Steed, Esther Herpel, Michael S Anglesio, Bonnie Zhang, Neil Lambie, Anthony J Swerdlow, Jan Lubinski, Robert A Vierkant, Ellen L Goode, Usha Menon, Aleksandra Toloczko-Grabarek
Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The..
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Monica Tang, Rachel L O'Connell, Frederic Amant, Philip Beale, Orla McNally, Katrin M Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin, Tania Moujaber, Catherine J Kennedy, Anna deFazio, King Tan, Yoland Antill, Jeffrey Goh, Tony Bonaventura, James Scurry, Michael Friedlander
OBJECTIVE: Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borde..
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Peter F Rambau, Robert A Vierkant, Maria P Intermaggio, Linda E Kelemen, Marc T Goodman, Esther Herpel, Paul D Pharoah, Stefan Kommoss, Mercedes Jimenez-Linan, Beth Y Karlan, Aleksandra Gentry-Maharaj, Usha Menon, Susanna Hernando Polo, Francisco J Candido dos Reis, Jennifer Anne Doherty, Simon A Gayther, Raghwa Sharma, Melissa C Larson, Paul R Harnett, Emma Hatfield
We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it..
Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer
MoonSun Jung, Amanda J Russell, Catherine Kennedy, Andrew J Gifford, Kylie-Ann Mallitt, Siva Sivarajasingam, David D Bowtell, Anna DeFazio, Michelle Haber, Murray D Norris, Michelle J Henderson
Background: The Myc oncogene family has been implicated in many human malignancies and is often associated with particularly aggre..
Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study
Brian Z Ring, Rajmohan Murali, Robert A Soslow, David DL Bowtell, Sian Fereday, Anna Defazio, Nadia Traficante, Catherine J Kennedy, Alison Brand, Raghwa Sharma, Paul Harnett, Goli Samimi
Background: Chemoresistance is a major challenge in ovarian cancer treatment, resulting in poor survival rates. Identifying marker..
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Dale W Garsed, Kathryn Alsop, Sian Fereday, Catherine Emmanuel, Catherine J Kennedy, Dariush Etemadmoghadam, Bo Gao, Val Gebski, Valerie Gares, Elizabeth L Christie, Maartje CA Wouters, Katy Milne, Joshy George, Ann-Marie Patch, Jason Li, Gisela Mir Arnau, Timothy Semple, Sreeja R Gadipally, Yoke-Eng Chiew, Joy Hendley
Purpose: Women with epithelial ovarian cancer generally have a poor prognosis; however, a subset of patients has an unexpected dra..
Dose-Response Association of CD8( ) Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Ellen L Goode, Matthew S Block, Kimberly R Kalli, Robert A Vierkant, Wenqian Chen, Zachary C Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Toloczko, Alexander Hein, Aliecia L Bouligny, Allan Jensen, Ana Osorio, Andreas D Hartkopf, Andy Ryan, Anita Chudecka-Glaz, Anthony M Magliocco, Arndt Hartmann, Audrey Y Jung, Bo Gao, Brenda Y Hernandez
Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; howev..
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Sharon E Johnatty, Jonathan P Tyrer, Siddhartha Kar, Jonathan Beesley, Yi Lu, Bo Gao, Peter A Fasching, Alexander Hein, Arif B Ekici, Matthias W Beckmann, Diether Lambrechts, Els Van Nieuwenhuysen, Ignace Vergote, Sandrina Lambrechts, Mary Anne Rossing, Jennifer A Doherty, Jenny Chang-Claude, Francesmary Modugno, Roberta B Ness, Kirsten B Moysich
PURPOSE: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymo..
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey, Karin S Kassahn, Felicity Newell, Michael CJ Quinn, Stephen Kazakoff, Kelly Quek, Charlotte Wilhelm-Benartzi, Ed Curry, Huei San Leong, Anne Hamilton, Linda Mileshkin
Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatm..
ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer
Ellen L Hedditch, Bo Gao, Amanda J Russell, Yi Lu, Catherine Emmanuel, Jonathan Beesley, Sharon E Johnatty, Xiaoqing Chen, Paul Harnett, Joshy George, Rebekka T Williams, Claudia Flemming, Diether Lambrechts, Evelyn Despierre, Sandrina Lambrechts, Ignace Vergote, Beth Karlan, Jenny Lester, Sandra Orsulic, Christine Walsh
BACKGROUND: ATP-binding cassette (ABC) transporters play various roles in cancer biology and drug resistance, but their associatio..
High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
Lars O Baumbusch, Aslaug Helland, Yun Wang, Knut Liestol, Marci E Schaner, Ruth Holm, Dariush Etemadmoghadam, Kathryn Alsop, Pat Brown, Gillian Mitchell, Sian Fereday, Anna DeFazio, David DL Bowtell, Gunnar B Kristensen, Ole Christian Lingjaerde, Anne-Lise Borresen-Dale
Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent studies ha..
LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
Prue A Cowin, Joshy George, Sian Fereday, Elizabeth Loehrer, Peter Van Loo, Carleen Cullinane, Dariush Etemadmoghadam, Sarah Ftouni, Laura Galletta, Michael S Anglesio, Joy Hendley, Leanne Bowes, Karen E Sheppard, Elizabeth L Christie, Richard B Pearson, Paul R Harnett, Viola Heinzelmann-Schwarz, Michael Friedlander, Orla McNally, Michael Quinn
High-grade serous cancer (HGSC), the most common subtype of ovarian cancer, often becomes resistant to chemotherapy, leading to po..